EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence

Rafi Kabarriti, Shane Lloyd iD, James Jabalee iD, Catherine Del Vecchio Fitz iD, Randa Tao, Tyler Slater, Corbin Jacobs iD, Sean Inocencio, Michael Rutenberg iD, Chance Matthiesen, Kasha Neff iD, Gene-Fu Liu und 2 weitere

Cancers · 08.01.2025 · 17 (2) · 174

DOI: 10.3390/cancers17020174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 08.01.2025. Verfasst von Rafi Kabarriti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Medical Center, Bronx, NY 10467, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The incidence and mortality of anal squamous cell carcinoma (ASCC) are rising, with greater than 80% of cases linked to human papillomavirus (HPV), primarily HPV16. Post-treatment surveillance can be challenging due to the limitations of anoscopy, digital anal rectal exam (DARE), and imaging. Plasma tumor tissue modified viral (TTMV)-HPV DNA has shown strong sensitivity, specificity, and predictive value in detecting the recurrence of HPV-driven oropharyngeal cancer. Here, we investigate the ability of TTMV-HPV DNA for the early recurrence detection of ASCC.

Methods

This retrospective clinical case series included 117 patients with HPV-driven ASCC across 7 U.S. centers, monitored with TTMV-HPV DNA during routine clinical care between March 2020 and June 2024. Physician-reported clinical data and biomarker testing data were combined to create a comprehensive, longitudinal dataset for evaluating test performance metrics.

Results

Patients had a median age of 63 years and median post-diagnosis follow-up of 19 months. HPV status was primarily confirmed by TTMV-HPV DNA (52%) or p16 immunohistochemistry (39%). Of those tested for TTMV-HPV DNA pretreatment, 85% had a positive result. TTMV-HPV DNA clearance during or within three months post-treatment was associated with significantly better recurrence-free survival. The per-patient surveillance sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 82.8%, 98.4%, 96.0%, and 92.5%. Of 24 patients with a documented recurrence and a positive TTMV-HPV DNA test, the test was the first evidence of recurrence in 14 patients (58.3%), with a median lead time of 59 days (range: 10–536). TTMV-HPV DNA accurately resolved 94.3% of cases with indeterminate clinical findings.

Conclusions

TTMV-HPV DNA testing provides a sensitive and specific approach for detecting patients with recurrent ASCC and resolving the status of patients with indeterminate clinical findings.

Schlagwörter

Stichwörter der Autor:innen

TTMV-HPV DNAanal cancercancer recurrence

Autor:innen und Institutionen

  • Montefiore Medical Center, Bronx, NY 10467, USA.
  • Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT 84113, USA.
  • Naveris, Inc., Waltham, MA 02451, USA.
  • Cancer Care Northwest, Spokane Valley, WA 99216, USA.
  • Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Freeman Radiation Oncology, Joplin, MO 64804, USA.

ORCID-Profile: Shane Lloyd, James Jabalee, Catherine Del Vecchio Fitz, Corbin Jacobs, Michael Rutenberg, Kasha Neff, Tiffany M Juarez, Stanley L Liauw

Zitieren

APA

Kabarriti, R., Lloyd, S., Jabalee, J., Del Vecchio Fitz, C., Tao, R., Slater, T., Jacobs, C., Inocencio, S., Rutenberg, M., Matthiesen, C., Neff, K., Liu, G. F., Juarez, T. M., & Liauw, S. L. (2025). Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence. Cancers, 17(2), 174. https://doi.org/10.3390/cancers17020174

Vancouver

Kabarriti R, Lloyd S, Jabalee J, Del Vecchio Fitz C, Tao R, Slater T, et al. Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence. Cancers. 2025;17(2):174. doi:10.3390/cancers17020174

BibTeX
@article{Kabarriti2025,
  author = {Kabarriti, Rafi and Lloyd, Shane and Jabalee, James and Del Vecchio Fitz, Catherine and Tao, Randa and Slater, Tyler and Jacobs, Corbin and Inocencio, Sean and Rutenberg, Michael and Matthiesen, Chance and Neff, Kasha and Liu, Gene-Fu and Juarez, Tiffany M and Liauw, Stanley L},
  title = {Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {2},
  pages = {174},
  doi = {10.3390/cancers17020174}
}
Kostenlos starten →